Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
3 minute read
  • Events
  • FDA
  • News

Merus Presents Clinical Data On Zenocutuzumab In NRG1-fusion (NRG1+) Cancers At 2021 ASCO Meeting

By Benzinga Newsdesk
Today, 5:34 PM
Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and

MRUS

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

Amgen’s Stomach Cancer Drug Acquired in Five Prime Buyout Extends Patients’ Lives, Mid-Stage Study Shows

By Vandana Singh
Today, 5:34 PM
Amgen Inc (NASDAQ:AMGN) has announced updated results for investigational bemarituzumab combined with chemotherapy from the Phase 2 FIGHT trial in patients…

AMGN

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • News
  • Offerings
  • Penny Stocks
  • Small Cap

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

By Vandana Singh
Today, 5:34 PM
Cyclerion Therapeutics Inc (NASDAQ:CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ:AKBA) for the development and commercialization of…

AKBA

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

FDA Expands EUA for Lower Dose Subcutaneous Version of Regeneron’s COVID-19 Antibody Cocktail

By Vandana Singh
Today, 5:34 PM
The FDA has authorized a new, lower-dose version of Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) COVID-19 monoclonal antibody cocktail for those with COVID-19 who…

REGN

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Small Cap

Surface Oncology’s SRF388 Shows Promising Anticancer Activity in Pretreated Patients

By Vandana Singh
Today, 5:34 PM
Surface Oncology (NASDAQ:SURF) has announced new data from the ongoing Phase 1 studies of SRF388 and SRF617. SRF388 data will be…

SURF

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

4D pharma To Stop Testing Asthma Med in COVID-19 Patients

By Vandana Singh
Today, 5:34 PM
4D pharma plc (NASDAQ: LBPS) has completed its target enrollment of 30 patients for Part A of its Phase 1/2 trial of MRx-4DP0004 in patients with partly controlled asthma.

LBPS

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

Sanofi Inks Partnership for Late-Stage Trial of Amcenestrant as Add-On Breast Cancer Therapy

By Vandana Singh
Today, 5:34 PM
Sanofi SA (NASDAQ:SNY) has secured partners for a Phase 3 trial to study amcenestrant versus the hormone therapy tamoxifen in breast…

SNY

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • News
  • Small Cap

Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer

By Vandana Singh
Today, 5:34 PM
Surface Oncology (NASDAQ:SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC:RHHBY) to evaluate former’s SRF388, anti-IL-27 antibody, in combination…

RHHBF

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Small Cap

Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial

By Vandana Singh
Today, 5:34 PM
Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ:CHRS) have announced positive results from the pivotal Phase 3 JUPITER-02 trial evaluating toripalimab…

CHRS

Read More
5 minute read
  • Biotech
  • FDA
  • News
  • Penny Stocks
  • Small Cap

The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact

By Shanthi Rexaline
Today, 5:34 PM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3)

ALLO

Posts navigation

Previous 1 … 1,038 1,039 1,040 … 1,053 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service